The course of the eye lesion after 1311 therapy appears to be independent of the progress of the associated thyroid disturbance and more closely related to the duration of history before treatment. Only two patients were demonstrated to have a total thyroid ablation, and in both small increases in measured exophthal3nos were observed.
It is clear that exophthalmos tends to increase in the majority of patients following treatment of thyrotoxicosis and regresses in very few. There is no evidence that the changes observed are specific for 131 and only large studies involving patients treated by surgery or antithyroid drugs will clarify this point. Mr Brian Martin' and Mr Barrie Jay (Department of Ophthalmology, The Lonidon Hospital, London)
Use of Guanetliidine Eye Drops in Dysthyroid Lid Retraction
Since lid retraction was first described in the middle of the nineteenth century as a sign of thyroid disease, ther-e has been much discussion and some argument about the actual mechanism of this retraction of the upper eyelid, and two major hypotheses for its pathogenesis have been proposed. These are, first, an overaction of the striated levator palpebrx superioris and, secondly, excessive stimulation of Muller's muscle by a state of sympathicotonia. The sympathicotonia possibly results from inhibition of liver monoamine oxidase synthesis by the high circulating levels of thyroxine. However, the presence of lid retraction in clinically euthyroid patients with dysthyroid eye signs cannot easily be accounted for on this second theory. Moreover, the eye findings are often unilateral.
'Present address: The General Infirmary, Leeds Guanethidine, which interferes selectively with adrenergic transmission at postganglionic nerve endings, was first instilled into the conjunctival sac as eye drops by Dorian & Schirmer (1964) , who noticed that ptosis, miosis and conjunctival vascular dilatation were produced on the treated side. In 1966 Sneddon & Turner in this country and Gay & Wolkstein in the United States described the use of guanethidine eye drops in the treatment of endocrin-e lid retraction, with encouraging results. Ten of Sneddon & Turner's 14 patients were untreated toxic ones, while the other 4 had recently been started on carbimazole; in Gay & Wolkstein's series 3 of the 7 patients were toxic.
Patients Studied and Methods
In the series of patients we have treated with guanethidine eye drops at The London Hospital, the majority of the 19 patients were euthyroid at the time of their treatment by us. Only 3 patients were on antithyroid medication. The average time from the treatment of thyrotoxicosis to the start of guanethidine therapy was four years. The longest interval was twenty years and only 4 patients were treated for thyrotoxicosis within the year prior to our trial. The 3 patients who were not euthyroid at the start of the trial were being treated with carbimazole, the remainder having originally been rendered euthyroid either by radioactive iodine or by subtotal thyroidectomy. All the patients in this series had lid retraction and lid lag and some had proptosis. The signs were unilateral in 6 cases.
The earlier patients were treated with 10% guanethidine once daily, increasing to twice or even three times daily if there was no improvement and in the absence of side-effects. Later patients were treated with the 50 solution when this became available. A full-face life-size black and white photograph with the patient looking straight ahead was taken before the treatment with guanethidine was started and progress was followed by serial photography.
Results
Of the 19 patients treated 12 (63 %) showed improvement in the position of the upper lid while all except one remarked that their eyes felt less tight and gritty and that lid closure was easier. In addition, one patient who had a subtotal thyroidectomy in 1963, with ocular signs since that time, noticed a remarkable disappearance of lid aedema within a week of starting guanethidine therapy. There was no change in the degree of proptosis as measured with the Hertel exophthalmometer in any of the patients.
Several previous authors noticed the production of a contralateral ptosis in cases where only one eye was being treated. This may be due either to systemic absorption of guanethidine or to a readjustment of sympathetic activity (Sneddon & Turner 1966). One of our patients, a 42-year-old woman, had radioactive iodine treatment for her thyrotoxicosis in 1965 and a year later developed a left-sided proptosis with lid retraction and lid lag. She also had a mild congenital right ptosis. After treatment for two months with 10% guanethidine twice daily to the left eye, there was improvement in the position of the left upper lid but the right ptosis became more marked.
Miotic pupils were produced in all patients using these drops, but none complained of visual symptoms as a result of this.
A repeated finding in this series was that, although there is often a good response to treatment within a week or ten days, with continued therapy the improvement often proceeds further for some months.
Conjunctival vascular dilatation has been a problem in some cases; it was so marked in 3 of the 19 patients that the guanethidine had to be discontinued; in other cases reduction of dosage resulted in relief of symptoms. This vascular dilatation has also been a problem with bethanidine drops, which have been given a trial more recently. Bethanidine, which is pharmacologically similar to guanethidine, appears to be of equal efficiency in the treatment of dysthyroid lid retraction. Punctate corneal erosions have been described as a toxic effect of local guanethidine therapy, but were not noted in this series.
Guanethidine has been found to reduce lid retraction in patients who are thyrotoxic, and this brief trial confirms that guanethidine also reduces lid retraction in euthyroid patients. The results of guanethidine therapy are unpredictable and there appears to be no common factor operating in those patients in whom it does not work. It is most important to emphasize that it does not replace other more conventional methods of medical and surgical treatment when corneal exposure is present. 
Effect of Thyroid Ablation on Dysthyroid Exophthalmos
It has recently been claimed that total removal or destruction of the thyroid gland is beneficial in cases of dysthyroid exophthalmos (Catz & Perzik 1965 , Bauer & Catz 1966 . The finding by some workers (McKenzie 1961 , Noguchi et al. 1964 , Pinchera et al. 1965 ) that significant titres of long-acting thyroid stimulator (LATS) are more commonly found in the serum of thyrotoxic patients with eye signs than in those without has led to the conjecture that LATS may have a causal role in the development of this complication. This situation, together with the finding that LATS is a thyroid specific antibody (Kriss et al. 1964 , Dorrington et al. 1966 , provided some rationale for the hypothesis that removal of all thyroid tissue from patients with severe dysthyroid exophthalmos might lead to a reduction in LATS levels and a concomitant improvement in the eye signs.
In March 1966 a working party of the Medical Research Council decided that the claims made for the beneficial effects of thyroid ablation were of sufficient importance to justify a controlled trial of this treatment. A parallel study was also to be made on the effect of thyroid ablation on the level of LATS in serum.
Outlinie of the MRC Tr-ial Patients with dysthyroid exophthalmos were randomly allocated to an ablation group and to a control group, the sole restriction on therapy being that thyroid ablation was not employed in the control group. Either surgical or radioiodine ablation was permitted, the latter being used in the patients described here. A detailed schedule for radioiodine therapy was issued, the main features being: (1) Only patients with eye signs of less than six months duration were included. (2) In order to minimize the total body radiation dose radioiodine ablation was carried out in a piecemeal fashion with an initial dose of up to 15 mc 1311 to control thyrotoxicosis and further similar doses of 1311 at two-month intervals thereafter until the 24-hour thyroid uptake was less than 3000O of the dose. Ablation doses of up to 100 mc 1311 were then given at six-monthly intervals until a five-day uptake of less than 0 2 00 of a 5 mc dose of 131J (preceded by thyrotrophin) was achieved.
